Table 1.
Compounds | Antiviral activity (EC50 b ) | Cytotoxicity (MCC c ) |
---|---|---|
7a | >100 | >100 |
7b | >100 | >100 |
7c | >100 | >100 |
7d | >100 | ≥100 |
7e | >100 | >100 |
7f | >100 | >100 |
7g | >100 | >100 |
7h | >100 | >100 |
7i | >100 | >100 |
7j | >100 | >100 |
7k | >100 | >100 |
7l | >100 | >100 |
7m | 31 ± 1 | >100 |
7n | 12 ± 1 | 100 |
8a | >100 | >100 |
8b | >100 | >100 |
8c | >100 | >100 |
8d | >100 | >100 |
8e | >100 | >100 |
8f | >100 | >100 |
8g | >100 | >100 |
8h | >100 | 100 |
8i | >100 | >100 |
8j | >100 | >100 |
8k | 28 ± 0 | >100 |
8l | 18 ± 5 | ≥100 |
8m | 8.1 ± 2.2 | 100 |
8n | 5.5 ± 0.7 | ≥100 |
8o | >100 | >100 |
8p | 6.1 ± 0.2 | 50 |
K22 | 3.3 ± 1.0 | 50 |
Data represent the averages ± SEM of 3–4 independent tests.
HEL: human embryonic lung fibroblast cells.
EC50: compound concentration (µM) producing 50% inhibition of virus replication, as determined by microscopic scoring of the cytopathic effect (CPE).
MCC: minimum cytotoxic concentration (µM), that is, compound concentration producing minimal changes in cell morphology, as estimated by microscopy.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.